Latest News
Antengene reports first patient dosed in Phase I study of ATG-201 in B cell-mediated autoimmune diseases
6 November 2026 - Commercial-stage biotech company Antengene Corporation Limited (SEHK:6996) announced on Thursday that the first patient has been dosed in China in the Phase I ATTRACT study evaluating ATG-201, Antengene's proprietary CD19 x CD3...
Akeso publishes ivonescimab Phase II study results in Nature Medicine
6 November 2026 - Chinese pharmaceutical company Akeso Inc (HKEX:9926) announced on Thursday that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibody ivonescimab in the perioperative treatment of resecta...
INOVIO prices public offering of approximately USD75m
6 November 2026 - INOVIO Pharmaceuticals Inc (Nasdaq:INO), a biotechnology company focused on developing and commercialising DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, announced on Thurs...
Chinese regulator accepts Lynk Pharmaceuticals' New Drug Application for zemprocitinib in RA treatment
6 November 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug company focused on autoimmune and inflammatory diseases, announced on Thursday that the New Drug Application (NDA) for its core product, zemprocitinib capsules, for the t...
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
5 November 2026 - French biotech company Transgene (Euronext Paris:TNG) and the University of Copenhagen have dosed the first patient in the Phase 1 OV-PRIME-R trial evaluating BT-001 in patients with localised rectal cancer, Transgene announced on T...